George Warimwe

Assessing the Level and Determinants of COVID-19 Vaccine Confidence in Kenya.Orangi S, Pinchoff J, Mwanga D, Abuya T, Hamaluba M, Warimwe G, Austrian K, Barasa E
Vaccines (Basel), (2021). 9:936

Tracking the introduction and spread of SARS-CoV-2 in coastal Kenya.Githinji G, de Laurent ZR, Mohammed KS, Omuoyo DO, Macharia PM, Morobe JM, Otieno E, Kinyanjui SM, Agweyu A, Maitha E, Kitole B, Suleiman T, Mwakinangu M, Nyambu J, Otieno J, Salim B, Kasera K, Kiiru J, Aman R, Barasa E, Warimwe G, Bejon P, Tsofa B, Ochola-Oyier LI, Nokes DJ, Agoti CN
Nat Commun, (2021). 12:4809

What Constitutes Protective Immunity Following Yellow Fever Vaccination?.Mokaya J, Kimathi D, Lambe T, Warimwe GM
Vaccines (Basel), (2021). 9:671

Temporal trends of SARS-CoV-2 seroprevalence during the first wave of the COVID-19 epidemic in Kenya.Adetifa IMO, Uyoga S, Gitonga JN, Mugo D, Otiende M, Nyagwange J, Karanja HK, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Bottomley C, Kagucia EW, Gallagher KE, Etyang A, Voller S, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM
Nat Commun, (2021). 12:3966

Using cross-species vaccination approaches to counter emerging infectious diseases.Warimwe GM, Francis MJ, Bowden TA, Thumbi SM, Charleston B
Nat Rev Immunol, (2021). 21:815-822

Endemic chikungunya fever in Kenyan children: a prospective cohort study.Nyamwaya DK, Otiende M, Omuoyo DO, Githinji G, Karanja HK, Gitonga JN, de Laurent ZR, Otieno JR, Sang R, Kamau E, Cheruiyot S, Otieno E, Agoti CN, Bejon P, Thumbi SM, Warimwe GM
BMC Infect Dis, (2021). 21:186

Immunogenicity and safety of fractional doses of yellow fever vaccines: a randomised, double-blind, non-inferiority trial.Juan-Giner A, Kimathi D, Grantz KH, Hamaluba M, Kazooba P, Njuguna P, Fall G, Dia M, Bob NS, Monath TP, Barrett AD, Hombach J, Mulogo EM, Ampeire I, Karanja HK, Nyehangane D, Mwanga-Amumpaire J, Cummings DAT, Bejon P, Warimwe GM, Grais RF
Lancet, (2021). 397:119-127

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, Aman R, Mwangangi M, Amoth P, Kasera K, Ng'ang'a W, Rombo C, Yegon C, Kithi K, Odhiambo E, Rotich T, Orgut I, Kihara S, Otiende M, Bottomley C, Mupe ZN, Kagucia EW, Gallagher KE, Etyang A, Voller S, Gitonga JN, Mugo D, Agoti CN, Otieno E, Ndwiga L, Lambe T, Wright D, Barasa E, Tsofa B, Bejon P, Ochola-Oyier LI, Agweyu A, Scott JAG, Warimwe GM
Science, (2021). 371:79-82

Urban Ecology of Arboviral Mosquito Vectors Along the Kenyan Coast.Karisa J, Muriu S, Omuoyo D, Karia B, Ngari M, Nyamwaya D, Rono M, Warimwe G, Mwangangi J, Mbogo CM
J Med Entomol, (2021). 58:428-438

Comparative performance of WANTAI ELISA for total immunoglobulin to receptor binding protein and an ELISA for IgG to spike protein in detecting SARS-CoV-2 antibodies in Kenyan populations..Nyagwange J, Kutima B, Mwai K, Karanja HK, Gitonga JN, Mugo D, Uyoga S, Tuju J, Ochola-Oyier LI, Ndungu F, Bejon P, Agweyu A, Adetifa IMO, Scott JAG, Warimwe GM
1st International Conference on Public Health in Africa (CPHIA), (2021). :

Prevalence of anti-SARS-CoV-2 IgG antibodies among Kenyan blood donors between June and August 2021..Uyoga S, Otiende M, Adetifa IMO, Karanja HK, Gitonga J, Mugo D, Makale J, Tawa B, Singilai A, Nyagwange J, Tuju J, Aman R, Mwangangi M, Amoth P, Kasera K, Ng�ang�a W, Kilonzo N, Chege E, Yegon C, Rotich T, Orgut I, Kagucia EW, Gallagher KE, Etyang A, Voller S, Bottomley C, Lambe T, Wright D, Tsofa B, Mwangangi J, Barasa E, Bejon P, Ochola-Oyier LI, Warimwe GM, Scott JAG, Agweyu A
1st International Conference on Public Health in Africa (CPHIA), (2021). :

High anti-SARS-CoV-2 IgG antibody seroprevalence among long-distance trucking crews in Kenya within one year of the COVID-19 pandemic..Kagucia EW, Gitonga JN, Kalu C, Kuya N, Ochieng B, Karia B, Ochomo E, Karani A, Nyagwange J, Mugo D, Karanja HK, Tuju J, Mutiso A, Maroko H, Okubi L, Maitha E, Mukabi D, The TDA SARS-CoV-2 Serosurveillance Team, Aman R, Mwangangi M, Amoth P, Kasera K, Ng�ang�a W, Nyaguara A, Voller S, Otiende M, Bottomley C, Agoti CN, Ochola-Oyier LI, Adetifa IMO, Etyang AO, Gallagher KE, Uyoga S, Barasa E, Bejon P, Tsofa B, Agweyu A, Warimwe GM, Scott JAG
1st International Conference on Public Health in Africa (CPHIA), (2021). :

Serosurveillance for SARS-CoV-2 Antibodies in a cohort of Health Care Workers in Kenya..Etyang AO, Lucinde R, Gitonga JN, Kalu C, Karani A, Nyagwange J, Mugo D, Karanja HK, Tuju J, Mutiso A, Maroko H, Okubi L, Maitha E, Mukabi D, The HCW SARS-CoV-2 Serosurveillance Team, Aman R, Mwangangi M, Amoth P, Kasera K, Ng�ang�a W, Nyaguara A, Voller S, Otiende M, Bottomley C, Agoti CN, Ochola-Oyier LI, Adetifa IMO, Gallagher KE, Uyoga S, Barasa E, Bejon P, Tsofa B, Agweyu A, Warimwe GM, Scott JAG
1st International Conference on Public Health in Africa (CPHIA), (2021). :

Genomic surveillance of SARS-CoV-2 in Kenya: March 2020-October 2021..Githinji G, Lambisia WA, Mohamed KS, Morobe MJ, de Laurent ZR, Mburu WM, Ongera ME, Omuoyo OD, Ndwiga L, Otieno E, Murunga N, Musyoki J, KWTRP COVID Testing Team, Kilifi Rapid Response Team, Kiiru J, Kasera K, Amoth P, Mwangangi M, Aman R, Kinyanjui S, Warimwe GM, Agweyu A, Barasa E, Tsofa B, Mwangangi J, Matoke D, Nokes DJ, Bejon P, Ochola-Oyier LI, Agoti CN
1st International Conference on Public Health in Africa (CPHIA-2021), (2021). :

Naturally Acquired Rift Valley Fever Virus Neutralizing Antibodies Predominantly Target the Gn Glycoprotein.Wright D, Allen ER, Clark MHA, Gitonga JN, Karanja HK, Hulswit RJG, Taylor I, Biswas S, Marshall J, Mwololo D, Muriuki J, Bett B, Bowden TA, Warimwe GM
iScience, (2020). 23:101669

Exploring Plasmodium falciparum Var Gene Expression to Assess Host Selection Pressure on Parasites During Infancy.Kivisi CA, Muthui M, Hunt M, Fegan G, Otto TD, Githinji G, Warimwe GM, Rance R, Marsh K, Bull PC, Abdi AI
Front Immunol, (2019). 10:2328

Safety and efficacy of ChAdOx1 RVF vaccine against Rift Valley fever in pregnant sheep and goats.Stedman A, Wright D, Wichgers Schreur PJ, Clark MHA, Hill AVS, Gilbert SC, Francis MJ, van Keulen L, Kortekaas J, Charleston B, Warimwe GM
NPJ Vaccines, (2019). 4:44

Rift Valley fever: biology and epidemiology.Wright D, Kortekaas J, Bowden TA, Warimwe GM
J Gen Virol, (2019). 100:1187-1199

Antigenic cartography of immune responses to Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1).Tuju J, Mackinnon MJ, Abdi AI, Karanja H, Musyoki JN, Warimwe GM, Gitau EN, Marsh K, Bull PC, Urban BC
PLoS Pathog, (2019). 15:e1007870

Simian adenovirus vector production for early-phase clinical trials: A simple method applicable to multiple serotypes and using entirely disposable product-contact components.Fedosyuk S, Merritt T, Peralta-Alvarez MP, Morris SJ, Lam A, Laroudie N, Kangokar A, Wright D, Warimwe GM, Angell-Manning P, Ritchie AJ, Gilbert SC, Xenopoulos A, Boumlic A, Douglas AD
Vaccine, (2019). 37:6951-6961